您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

Non-clinical Research-used
Medicine Sample Provider
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 加拿大药房
产地国家: 加拿大
所属类别: 糖尿病->2型糖尿病
处方药:处方药
包装规格: (2.5/500)毫克/片 60片/瓶
计价单位:
  点击放大  
生产厂家中文参考译名:
勃林格殷格翰
生产厂家英文名:
BOEHRINGER INGELHEIM
该药品相关信息网址1:
https://www.jentadueto.com/
该药品相关信息网址2:
https://www.jentadueto.com/
该药品相关信息网址3:
http://www.medilexicon.com/drugs/jentadueto.php
原产地英文商品名:
JENTADUETO (2.5/500)MG/TAB 60TABS/BOTTLE
原产地英文药品名:
LINAGLIPTIN/METFORMIN HCL
中文参考商品译名:
JENTADUETO (2.5/500)毫克/片 60片/瓶
中文参考药品译名:
利拉利汀/盐酸二甲双胍
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
Type 2 diabetes
临床试验期:
完成
中文适应病症参考翻译1:
2型糖尿病
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201251019274919.PDF)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文Jentadueto处方资料(仅供参考)

FDA批准Jentadueto™ 片应用于成人2型糖尿病治疗
    勃林格殷格翰公司和礼来公司近日(NYSE: LLY)宣布Jentadueto™ (linagliptin/盐酸二甲双胍)片已经获得了美国食品和药品管理局 (FDA)的批准,该药是二肽基肽酶-4 (DPP-4)抑制剂 linagliptin和二甲双胍的新型复合片剂1。Linagliptin/盐酸二甲双胍的问世为需要改善血糖控制的2型糖尿病成年患者提供了全新的、每日服用两次的单一药片治疗选择1。 Linagliptin (5 mg,每日给药一次)已经在美国以Tradjenta™ (linagliptin)片的形式上市,在欧洲和加拿大则以Trajenta™ 为商品名上市,在日本和其他市场则以 Trazenta™ 为商品名上市2,3,目前在中国尚未上市。
  Linagliptin/盐酸二甲双胍治疗应基于饮食控制和体育锻炼之上,这一处方药物可应用于适合接受linagliptin和二甲双胍治疗的2型糖尿病成年患者,用以改善这些患者的血糖控制水平。在使用最大给药剂量的时候,linagliptin/盐酸二甲双胍可使得安慰剂校正的血红蛋白A1c(HbA1c 或 A1C)出现高达1.7%的降幅 (安慰剂组为+0.1%,linagliptin/盐酸二甲双胍组为-1.6%)。A1C 是糖尿病检测指标之一,可反映最近2个月到3个月的血糖控制水平。Linagliptin/盐酸二甲双胍不会导致任何具有临床意义的体重改变。Linagliptin/盐酸二甲双胍可单独使用,也可与2型糖尿病常用药物磺脲类药物联合使用。Linagliptin/盐酸二甲双胍不应用于1型糖尿病或糖尿病酮症酸中毒 (血液或尿液中的酮体含量增高),目前尚未对该药与胰岛素的联合使用开展过研究。Linagliptin/盐酸二甲双胍的产品标签中包含有关乳酸酸中毒的加框警示,乳酸酸中毒是一种严重的代谢性并发症,由linagliptin/盐酸二甲双胍治疗过程中产生的二甲双胍蓄积所导致1。
  “由于2型糖尿病具有复杂的发病机制,大多数2型糖尿病患者需要接受一种以上的药物治疗以降低其血糖水平,”来自德州肾脏和内分泌疾病研究所的 Lance Sloan博士如此说道。“Jentadueto™ 获得批准是一个令人兴奋的消息,因为这种药物将两种降糖药复合成为单一片剂,从而为那些需要一种以上药物治疗、而且适合接受linagliptin和二甲双胍的患者提供了很好的治疗选择。”

FDA批准两药复方片Jentadueto用于治疗2型糖尿病
    2012年1月30日,礼来公司和勃林格殷格翰公司宣布美国食品药品管理局(FDA)已批准Jentadueto(利拉利汀/盐酸二甲双胍)用于改善成人2型糖尿病患者的血糖控制。该药适合作为饮食和运动疗法的辅助用药,用于同时适宜采用利拉利汀和二甲双胍治疗的患者。Jentadueto既可以单独用药,也可以与磺酰脲联合用药。
    FDA批准利拉利汀/二甲双胍复方制剂是基于评价利拉利汀和二甲双胍作为单独片剂治疗糖尿病的临床试验结果。在最大剂量下,利拉利汀/二甲双胍组的血红蛋白A1c相对于安慰剂组的降幅达到1.7%(安慰剂组为+0.1%,利拉利汀/二甲双胍组为-1.6%)。健康受试者联合服用利拉利汀片和二甲双胍片显示与服用利拉利汀/二甲双胍复方制剂具有生物等效性。
    Jentadueto治疗组中有≥ 5%的患者报告发生不良反应,该比例大于安慰剂对照组,不良反应包括鼻咽炎和腹泻。Jentadueto+磺酰脲联合治疗组与安慰剂+磺酰脲+二甲双胍联合治疗组相比,其报告发生低血糖的患者比例较高(分别为22.9% vs. 14.8%)。在这些研究中,服用利拉利汀/二甲双胍与任何明显的体重变化均无相关性。
    Jentadueto的说明书中包含一个有关乳酸酸中毒的黑框警告。
    Jentadueto是一种口服片剂,每日服用2次。

礼来公司2型糖尿病用药Jentadueto在美上市
    勃林格殷格翰公司医药公司和礼来公司共同宣布Jentadueto(linagliptin/盐酸二甲双胍)片在美上市销售。
    Jentadueto一天服用两次,能够帮助患者控制血糖,这是一种结合两种糖尿病药物linagliptin/盐酸二甲双胍的复方药。
    美国食品药监局(FDA)于2012年1月30号批准Jentadueto上市销售,主要用于帮助2型糖尿病患者控制血液葡萄糖水平。
    Jentadueto不能用于治疗1型糖尿病或者糖尿病酮症酸中毒症,而且其结合胰岛素治疗的也没有得到验证。
    勃林格殷格翰公司公司心血管病副主席说:能够将两种有效的药物合成一种药,希望Jentadueto能够为2型糖尿病患者提供一种新的控制血糖的药物。在获得FDA批准后能够这么快将Jentadueto推向市场,主要是为了满足美国数以百万计的2型糖尿病患者的医疗需求.

Jentadueto (linagliptin plus metformin hydrochloride)
Company: Eli Lilly
Approval Status: Approved February 2012
Treatment for: type II diabetes
Areas: Diabetes / Endocrinology

General Information
Jentadueto is a fixed dose combination of linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, plus metformin, which helps to control the amount of glucose in the blood.

Jentadueto is specifically approved as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus when treatment with both linagliptin and metformin is appropriate.

Jentadueto is supplied as a tablet for oral administration. Jentadueto should be individualized on the basis of both effectiveness and tolerability, while not exceeding the maximum recommended dose of 2.5 mg linagliptin/1000 mg metformin twice daily. The recommended starting dose is as follows:
Subjects not currently treated with metformin: initiate treatment with 2.5 mg linagliptin/500 mg metformin hydrochloride twice daily
Subjects already treated with metformin: start with 2.5 mg linagliptin and the current dose of metformin taken at each of the two daily meals
Subjects already treated with linagliptin and metformin: individual components may be switched to Jentadueto containing the same doses of each component.

Clinical Results
FDA Approval
The FDA approval of Jentadueto was based on clinical trials that evaluated linagliptin and metformin as separate tablets. Bioequivalence of Jentadueto was demonstrated with co-administered linagliptin and metformin tablets in healthy subjects. A 24-week, randomized, double-blind, placebo-controlled factorial study enrolled 791 adults with type 2 diabetes and inadequate glycemic control with diet and exercise who received linagliptin plus metformin concurrently. At the maximum dose (2.5 mg linagliptin/1,000 mg metformin twice-daily) Jentadueto demonstrated placebo-corrected reductions in hemoglobin A(1c) (HbA(1c) levels of up to 1.7% (+0.1% for placebo and -1.6% for Jentadueto).

Side Effects
Adverse events associated with the use of Jentadueto may include, but are not limited to, the following:
nasopharyngitis
diarrhea
hypoglycemia
pancreatitis

Mechanism of Action
Jentadueto is a fixed dose combination of linagliptin plus metformin. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibito. DDP-4 is an enzyme that degrades the incretin hormones glucagon-like-peptide-1 (GLP-1) and glucose-dependent insulinotrophic polypeptide. Thus, linagliptin increases the concentrations of active incretin hormones, stimulating the increase of insulin in a glucose-dependent manner and decreasing the levels of glucagon in the circulation. Metformin is an antihyperglycemic agent which improves glucose tolerance, lowering both basal and postprandial plasma glucose.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201251019274919.PDF)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2014-08-25
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15900659515@163.com